N/A N=162 Asian Outcomes of Primary Breast Augmentation
Breast Augmentation
Primary: Post Surgical Complications and Reoperation Rate During Breast Augmentation — 1.85; 1.85 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects
Healthy Subjects
Primary: AUC (0-t) of Plasma Metformin — 6164; 9014; 18709; 16989 ng*h/mL — p=<0.001
Phase 2 N=240 Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks
Type 2 Diabetes Mellitus
Primary: Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks — -4; -11; -13; -18 mg/dL — p=0.0670
Phase 4 N=11 The Effect of Glucomannan Soluble Fiber on Glucose Homeostasis in Patients With Roux En Y (RNY) Gastric Bypass Surgery
Hypoglycemia
Primary: Difference Score: Percent of Time Spent in Hypoglycemic State — 1.2 Difference score, trt-control (percent) — p=0.99
Phase 3 N=652 Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)
Hepatitis C
Primary: Sustained Virological Response 12 Weeks Post-treatment (SVR12) — 79.5; 80.5; 52.3 percentage of participants — p=<0.0001
Phase 2 N=30 Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants Who Achieved ASAS20 Response — 59.2; 24.5 Percentage
Phase 2 N=31 Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: Percentage of Patients With Progression-free Survival > 6 Months — 10 percentage of participants
Phase 3 N=136 Indacaterol EfectIveness In COPD Patients With Tuberculosis History
Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis
Primary: Trough Forced Expiratory Volume in One Second Change — 0.08; -0.06 Liters — p=<0.0001
Phase 2 N=54 Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
Leukemia
Primary: Response To Induction Therapy With Hyper-CVAD Plus Imatinib Mesylate — 42; 1; 17; 1 participants
N/A N=151 Safety and Effectiveness of the AcuFocus Corneal Inlay ACI7000PDT in Presbyopes
Presbyopia
Primary: Uncorrected Near Visual Acuity 20/32 or Better — 73.8 percentage of subjects
N/A N=144 The Difference in Cerebral Oxygenation Between Propofol and Sevoflurane
Cerebral Hypoxia · Postoperative Cognitive Dysfunction
Primary: the Incidence of Intraoperative Desaturation Between Propofol and Sevoflurane General Anesthesia — 17; 6; 6; 0 participants
Phase 2 N=32 Oral Clofarabine Study in Patients With Myelodysplastic Syndrome
Myelodysplastic Syndrome · Chronic Myelomonocytic Leukemia
Primary: Participants With a Complete Remission (CR) — 8; 3; 0; 0 Participants
N/A N=10 Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm
Nicotine Dependence · Healthy
Primary: Change in Dopamine Levels at Baseline and After Amphetamine Administration as Measured by Percent Change in PET Tracer Binding Potential. — -21; -29 percent change in…
Phase 3 N=658 Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)
Hepatitis C
Primary: Sustained Virologic Response 12 Weeks Post Treatment (SVR12) — 67.9; 64.3; 47.0 percentage of participants — p=<0.0001
N/A N=45 Brief Behavioral Intervention for Comorbid Migraine and Depression
Migraine · Depression
Primary: Mean Change in Hamilton Depression Rating Scale (HAM-D) From Baseline to 12 Week Follow-up — -15.1; -4.3 units on a scale